Profusa Converts Term Sheet into Binding Option to Acquire G3 Vision Labs, Issues Equity Consideration, and Targets Nasdaq Compliance

summarizeSummary

Profusa signed a binding option agreement to acquire G3 Vision Labs, paying immediate equity consideration that could lead to massive dilution if the option is exercised and preferred shares convert. The deal is contingent on raising $30 million and other conditions, while the company also claims it now meets Nasdaq's equity listing requirement.

check_boxKey Events · M&A and Partnerships · PFSA

• Binding Option Agreement Signed

  A binding option agreement to acquire G3 Vision Labs and its subsidiaries has been signed, replacing the non-binding term sheet announced July 27, 2026. The option is exercisable for 90 days after G3 delivers audited financials.

• Immediate Equity Consideration Issued

  As option consideration, 201,120 common shares and 52,903.566 shares of Series A Non-Voting Convertible Preferred Stock were issued. Each preferred share converts into 1,000 common shares upon stockholder approval, representing a potential issuance of ~52.9 million shares—a massive overhang relative to ~1.01 million shares currently outstanding.

• Exercise Conditions Include $30M Financing

  Exercising the option requires raising at least $30 million in financing, refinancing or repaying G3's debt, obtaining stockholder approvals for the conversion and Nasdaq listing rules, and maintaining Nasdaq listing. If these conditions are not met, the sellers keep the consideration but no acquisition occurs.

• Nasdaq Compliance Update

  The equity issuance is believed to have lifted stockholders' equity above $2.5 million, meeting an alternative Nasdaq continued listing standard. Formal confirmation from Nasdaq is pending.

auto_awesomeAnalysis · PFSA · Industrial Applications And Services

Profusa has transformed a non-binding term sheet into a binding option agreement to acquire G3 Vision Labs, a diagnostics company with estimated 2025 revenues of ~$111 million. The structure grants an option—not an obligation—but the consideration paid is immediate and non-refundable: 201,120 common shares and 52,903.566 shares of newly created Series A Preferred Stock. Each preferred share converts into 1,000 common shares upon stockholder approval, implying a potential 52.9 million additional shares, which would massively dilute existing holders given the current ~1.01 million shares outstanding. Exercising the option hinges on raising $30 million in financing, refinancing G3's debt, and securing stockholder approvals—all significant hurdles for a micro-cap company with a going concern warning and a recent reverse stock split. The filing also states the company believes it now meets Nasdaq's $2.5 million equity requirement, a critical lifeline after delisting threats. This is a high-stakes, transformative event that could either rescue the company or lead to severe dilution and control changes.